ACL australian clinical labs limited

Ann: Second letter from Crescent Capital, page-4

  1. 1,502 Posts.
    lightbulb Created with Sketch. 12
    Result was below consensus.
    Goldman have EPS of 34c in FY23 and 24c in FY24.
    "the key debate with the stock is the underlying (ex-Covid) profitability". GS think management are executing well.

    Not a holder but considering it.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
$2.80
Change
-0.035(1.24%)
Mkt cap ! $545.9M
Open High Low Value Volume
$2.83 $2.83 $2.78 $408.8K 146.3K

Buyers (Bids)

No. Vol. Price($)
13 12834 $2.79
 

Sellers (Offers)

Price($) Vol. No.
$2.80 2239 11
View Market Depth
Last trade - 11.26am 29/07/2025 (20 minute delay) ?
ACL (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.